A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer

Exclusion Criteria

• •Prior treatment with immunotherapy for any stage NSCLC, including early-stage (neoadjuvant or adjuvant) disease
• •Participants with epidermal growth factor receptor (EGFR) sensitizing mutations and anaplastic lymphoma kinase (ALK) rearrangements
• •Active central nervous system (CNS) metastases requiring treatment
• •Spinal cord compression not definitively treated or not clinically stable
• •Leptomeningeal disease
• •Uncontrolled tumor-related pain
• •Uncontrolled pleural, pericardial effusions, or ascites requiring recurrent drainage procedures
• •Uncontrolled or symptomatic hypercalcemia
• •Malignancies other than NSCLC within 5 years prior to enrollment, except for those curatively treated with negligible risk of metastasis or death
• •Pregnant or lactating women
• •History of autoimmune disease, significant pulmonary disease, or significant cardiovascular disease
• •Positive human immunodeficiency virus (HIV) or hepatitis B or C
• •Active tuberculosis
• •Severe infection or major surgery within 4 weeks, or oral or IV antibiotics treatment within 2 weeks prior to enrollment
• •Prior treatment with or hypersensitivity to study drug or related compounds
• •Prior allogeneic bone marrow or solid organ transplant
• •Administration of a live, attenuated vaccine within 4 weeks prior to enrollment
• •Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to enrollment
• •Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to enrollment